Uncategorized

Lilly’s triple agonist still leads among late-stage obesity assets

Lilly’s triple agonist still leads among late-stage obesity assets

Published

3 weeks ago

on

Many developers of obesity drugs are fond of saying that it’s not a competition to produce the strongest and fastest level of weight loss. They had better hope they’re right, because if it is a …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version